BSE - Delayed Quote INR

Krebs Biochemicals & Industries Limited (KREBSBIO.BO)

Compare
98.73
+4.70
+(5.00%)
At close: January 21 at 9:28:28 AM GMT+5:30
Loading Chart for KREBSBIO.BO
DELL
  • Previous Close 94.03
  • Open 98.73
  • Bid 98.73 x --
  • Ask --
  • Day's Range 98.73 - 98.73
  • 52 Week Range 60.00 - 129.00
  • Volume 25
  • Avg. Volume 6,855
  • Market Cap (intraday) 2.129B
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) --
  • EPS (TTM) -10.10
  • Earnings Date Feb 4, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Sep 14, 2005
  • 1y Target Est --

Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. The company was incorporated in 1991 and is based in Visakhapatnam, India.

krebsbiochem.com

191

Full Time Employees

March 31

Fiscal Year Ends

Recent News: KREBSBIO.BO

View More

Performance Overview: KREBSBIO.BO

Trailing total returns as of 1/21/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

KREBSBIO.BO
6.74%
S&P BSE SENSEX
3.08%

1-Year Return

KREBSBIO.BO
31.45%
S&P BSE SENSEX
5.80%

3-Year Return

KREBSBIO.BO
47.27%
S&P BSE SENSEX
27.54%

5-Year Return

KREBSBIO.BO
7.32%
S&P BSE SENSEX
82.62%

Compare To: KREBSBIO.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: KREBSBIO.BO

View More

Valuation Measures

Annual
As of 1/20/2025
  • Market Cap

    2.03B

  • Enterprise Value

    3.96B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.00

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    7.81

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -37.11%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    527.29M

  • Net Income Avi to Common (ttm)

    -195.67M

  • Diluted EPS (ttm)

    -10.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.37M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: KREBSBIO.BO

View More

Company Insights: KREBSBIO.BO

Research Reports: KREBSBIO.BO

View More

People Also Watch